IVERIC bio

IVERIC bio Dividend

Delisted

Dividend of IVERIC bio (ISEE) as of Oct 22, 2026.

Dividend

0.00USD

Last updated:

How much dividend does IVERIC bio 2026 pay?

According to the latest status from October 2026, IVERIC bio paid a total of 0.00 USD per share in dividends within the last 12 months. With the current IVERIC bio price of 0.00 USD, this corresponds to a dividend yield of - %. A dividend is paid times per year.

Historical IVERIC bio Dividends

Historical IVERIC bio Dividends
PaydateDividend

The IVERIC bio Dividend history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Date
Dividend
Jan 1, 2023 (e)
0.00 USD
Jan 1, 2024 (e)
0.00 USD
Jan 1, 2025 (e)
0.00 USD
Jan 1, 2026 (e)
0.00 USD
Jan 1, 2027 (e)
0.00 USD
Jan 1, 2028 (e)
0.00 USD
Jan 1, 2029 (e)
0.00 USD
Jan 1, 2030 (e)
0.00 USD
The IVERIC bio Dividend history
YEARDividendYoY
est0.00USD—
est0.00USD—
est0.00USD—
est0.00USD—
est0.00USD—
est0.00USD—
est0.00USD—
est0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—

Is the IVERIC bio Dividend Safe?

IVERIC bio has been increasing the dividend for 0 years.

Analysts expect a Dividend Cut of -100.00% for the current fiscal year.

Dividend Details

Understanding IVERIC bio's Dividend Distributions

IVERIC bio’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining IVERIC bio's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

IVERIC bio's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in IVERIC bio’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

IVERIC bio Stock analysis

What does IVERIC bio do? Iveric Bio Inc is a leading biopharmaceutical company specializing in the discovery and development of therapy options for eye diseases. The company was originally founded in 1989 as Ophthotech Corp. and is headquartered in New York City. Iveric Bio Inc aims to develop innovative treatments for eye diseases that can improve the lives of millions of people. The eye diseases that Iveric Bio Inc is fighting range from retinal diseases to degenerative eye diseases. Iveric Bio Inc has a strong business model, focusing on innovation to develop new treatment methods. The company invests in research and development to create a solid pipeline of new therapies, while also closely collaborating with the medical community to ensure that the therapies meet the needs of patients and doctors. Iveric Bio Inc's therapy options are focused on treating eye diseases such as age-related macular degeneration, diabetic retinopathy, and other retinal diseases. Iveric Bio Inc also focuses on preserving vision and improving the quality of life for people with glaucoma and other eye diseases. Iveric Bio Inc's portfolio currently includes two main products: Zimura and GATHER1. Zimura is a potentially groundbreaking medication developed for the treatment of dry age-related macular degeneration (AMD). It is currently being studied in late-stage clinical trials and could play an important role in the future of AMD treatment. GATHER1, the other main product of Iveric Bio Inc, is a clinical drug candidate developed for the treatment of geographic atrophy (GA). GA is an advanced form of dry AMD associated with the destruction of cells in the retina and a loss of vision. GATHER1 has been deemed promising in Phase II trials and is currently being tested in Phase III trials. Overall, Iveric Bio Inc has an excellent track record in the development of therapy options for eye diseases. The company has a wide range of treatment possibilities in the pipeline aimed at meeting the need for effective therapies for various eye diseases. Additionally, Iveric Bio Inc works closely with the medical community and other biopharmaceutical companies to share the latest research findings and advance the treatment of eye diseases. Overall, Iveric Bio Inc is an emerging biopharmaceutical company with a strong focus on research and development. The company has a strong business model and a robust pipeline of therapy options aimed at improving eye health and the quality of life for millions of people. IVERIC bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IVERIC bio stock

IVERIC bio is assigned to the 'Health' sector.

The dividends of IVERIC bio are distributed in USD.

Dividend calendar 2026

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

All Key Metrics — IVERIC bio